Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

d a two-stage min-max design in which if there were at least nine responses in the first 42 patients, the trial was to continue to the second stage. On January 25, 2007, the Company announced that there had been at least nine remissions in the first stage and that the trial would therefore continue. Eighty-five patients were enrolled in order to ensure that at least 77 would be eligible for the trial and included in the full analysis set. At least 22 responses in 77 patients are required to confirm the 35% target response rate with 95% confidence. If the full analysis set includes all 85 patients, then at least 24 responses are required for confirmation of the target response rate.

Dr. Dan DeAngelo, Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute and an investigator on the trial commented, "The treatment of elderly patients with poor-risk AML represents a significant unmet medical need in clinical oncology, and it is important that we find new effective treatment options. Agents such as Cloretazine(R) (VNP40101M) have the potential to address this need."

Dr. Gary Schiller, Professor of Medicine at the UCLA Geffen School of Medicine and an investigator on the trial added, "This was a very important study for older AML patients treated here at UCLA. As a single agent therapy administered over 30 to 60 minutes, Cloretazine(R) (VNP40101M) is clearly an active agent with the potential to play an important role in the treatment of this difficult population."

On August 8, 2007, the Company announced that certain sites on the trial would remain open and continue to accrue patients to an ECG sub-study. Recent FDA/ICH guidance recommends that an electrocardiographic evaluation (QT/QTc) study be included in the clinical development of all new drugs. Normally these studies are conducted in healthy subjects so that disease factors/co- morbidities do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe , ... , today announced that it now offers the revolutionary ... CPAPs are the first sleep apnea therapy devices with ... and easy to track and share real-time data on ... of their CPAP therapy.  In addition, the internal modem ...
(Date:9/30/2014)... The Chinese wound care market is in ... the incidence of lifestyle diseases, coupled with the increase ... better quality of wound care products provide the impetus ... public health insurance schemes and increased reimbursement rate for ... the findings of primary and secondary researches, this research ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), ... for the sale of Gastrodia valued at 67.5 Million ... are with Chongqing Valley Pharm Corp and Sichuan Zhiyuanguanghe ... of 550 tons of Gastrodia from January 1, 2012 to December ...
... Accuray Incorporated (Nasdaq: ARAY ), the ... study demonstrating the benefits of the CyberKnife® Robotic ... the treatment of central lung tumors using gantry based ... a great deal of accuracy to avoid risks of ...
Cached Medicine Technology:China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 3Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 2Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 3Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 4
(Date:9/30/2014)... partnership funded by the Department of Defense (DoD) ... better-run clinical trials and may lead to the ... condition affecting not only athletes and soldiers, but ... youngsters to elders. , Under the partnership, ... million, five-year award from the DoD, the research ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacy” (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Life Length ... provides CHL access to Life Length’s proprietary Telomere Analysis ... and comprehensive telomere test on the market today, and ... the percentage of short telomeres, providing the most critical ... Chairman of the Department of Cell Biology at The ...
(Date:9/30/2014)... 2014 Market Research Report on ... professional and in-depth market survey on Global and ... basic information of Cialis including its classification, application ... and China’s top manufacturers of Cialis listing their ... etc. , The report further analyzes quantitatively 2009-2014 ...
(Date:9/30/2014)... 30, 2014 Catalent Pharma Solutions ... delivery technologies and development solutions for drugs, biologics ... agenda for the 25th Annual CPhI Worldwide Exhibition ... 6th to 9th. , Catalent is showcasing a ... during the show, including its facilities in China ...
Breaking Medicine News(10 mins):Health News:US aims for traumatic brain injury clinical trial success 2Health News:US aims for traumatic brain injury clinical trial success 3Health News:US aims for traumatic brain injury clinical trial success 4Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3
... HIV case in Libya involving five Bulgarian nurses and a ... that they were tortured brutally to give false testimonies. ... when they were accused of starting an HIV epidemic in ... the infections have begun much before the arrival of these ...
... the better your heart health. But a man’s heart ... relationships among cholesterol levels,// psychological function, and neurologic disorders ... Harvard Men’s Health Watch. ,There are ... disease. Vascular dementia results when blood vessel damage deprives ...
... launched ‘The HumaPen Memoir’ the world's first digital insulin pen ... simplifies the management of diabetic patients who require timely insulin ... designed to meet the needs of people with diabetes who ... ,The unique pen memory device can help the patient to ...
... select patients for further testing may increase detection of ... colorectal cancer at a young age, //researchers report in ... National Cancer Institute. ,Lynch syndrome, also known ... mutations in DNA mismatch repair genes, the genes that ...
... key signaling protein in the brain during infancy could ... //According to findings published today in the journal Nature, ... serotonin just after birth exhibit abnormal anxiety as adults. ... mice genetically engineered to lack the receptor for serotonin, ...
... cases of dengue fever were reported across Paraguay in the ... new //cases a day last week, Paraguay's health authorities said ... has not yet declared the epidemic to be a health ... ,Dengue fever is a viral infection spread by the ...
Cached Medicine News:Health News:Mouse Study Suggests Anxiety Disorders Take Root in Infancy 2
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur....
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Bayonet Kerrison Rongeur, ceramic ejector, 9.5 length 40 Fwd, 6.5 working length 165 mm....
Medicine Products: